Actelion
Actelion Logo
Actelion Headquarters in Allschwil
Cotherix Logo
Actelion[edit | edit source]
Actelion was a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for diseases with significant unmet medical needs. The company was founded in December 1997 and was headquartered in Allschwil, Switzerland. Actelion was known for its work in the field of pulmonary arterial hypertension (PAH) and other rare diseases.
History[edit | edit source]
Actelion was established by a group of scientists and executives from Hoffmann-La Roche, including Jean-Paul Clozel, Martine Clozel, Walter Fischli, and Thomas Widmann. The company quickly gained recognition for its focus on orphan drugs and its innovative approach to drug development.
In 2000, Actelion launched its first product, bosentan (brand name Tracleer), which was the first oral treatment approved for PAH. This marked a significant milestone for the company and established its reputation in the field of cardiovascular disease.
In 2017, Actelion was acquired by Johnson & Johnson for $30 billion. The acquisition included Actelion's PAH portfolio, while its drug discovery operations and early-stage clinical development assets were spun off into a new company called Idorsia.
Products[edit | edit source]
Actelion developed several important drugs, primarily in the area of PAH and other rare diseases:
- Bosentan (Tracleer): An endothelin receptor antagonist used to treat PAH.
- Macitentan (Opsumit): Another endothelin receptor antagonist for PAH, offering improved efficacy and safety.
- Selexipag (Uptravi): An oral prostacyclin receptor agonist for the treatment of PAH.
- Iloprost (Ventavis): An inhaled prostacyclin analogue for PAH.
- Almorexant: An orexin receptor antagonist developed for the treatment of insomnia, though it was never marketed.
Research and Development[edit | edit source]
Actelion was heavily invested in research and development (R&D), focusing on innovative therapies for rare and orphan diseases. The company maintained a strong pipeline of investigational drugs and was involved in numerous clinical trials.
The company's R&D efforts were supported by its proprietary drug discovery platform, which enabled the identification of novel targets and the development of small molecule drugs.
Acquisition by Johnson & Johnson[edit | edit source]
In January 2017, Johnson & Johnson announced its intention to acquire Actelion for $30 billion. The acquisition was completed in June 2017, with Actelion's commercial operations becoming part of Johnson & Johnson's Janssen Pharmaceutical Companies. The deal was structured to allow Actelion's drug discovery operations to continue independently as Idorsia, a new company focused on early-stage drug development.
Related pages[edit | edit source]
- Pulmonary arterial hypertension
- Orphan drug
- Endothelin receptor antagonist
- Johnson & Johnson
- Idorsia
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
